
|Articles|August 1, 2006
Melanoma drug 'fast-tracked'
West Haven, Conn. - The kidney cancer drug Nexavar has been granted fast track designation by the Food and Drug Administration for treatment of advanced melanoma, manufacturer Bayer Pharmaceuticals announced.
Advertisement
West Haven, Conn. - The kidney cancer drug Nexavar has been granted fast track designation by the Food and Drug Administration for treatment of advanced melanoma, manufacturer Bayer Pharmaceuticals announced.
Nexavar was approved last year for treatment of renal cell carcinoma.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
FDA Clears IND Application of Recludix’s Oral STAT6, REX-8756
5

















